NG Biotech NG-test® Carba 5 Posters presented at local meetings

31 MARCH 2025

At Cell Biosciences, we are proud to support cutting-edge diagnostics in the field of infectious disease.

Recently, Nepean Hospital conducted a study on the NG Biotech NG-test® Carba 5 and presented their findings as a poster at the RCPA Pathology Update conference in Melbourne in February 2025.

The study, titled “Validation of Multiplex Lateral Flow Immunoassay NG-Test Carba 5 for the Rapid Identification of Carbapenemase-producing Organisms” aimed to validate the performance of the NG Biotech NG-test® Carba 5 lateral flow immunoassay for rapid detecting carbapenemase production (KPC-, NDM-, VIM-, IMP-type and OXA-48-like) in common clinical bacterial isolates.

The study concluded that NG-test® Carba 5 is a reliable, cost effective and quick turnaround assay for the detection of Carbapenemase. It facilitates efficient treatment decisions as well as rapid infection. Click here to view the poster.

This poster agrees with the findings of another recent poster presented at CliniCon 2024 by the Microbiological Diagnostic Unit, Department of Microbiology and Immunology at the Peter Doherty Institution for Infection and Immunity, where they found that the NG-test® CARBA-5 is a rapid and cost-efficient test to detect carbapenemases across numerous bacterial species and provides a useful resource in the identification/confirmation of CPOs. In the study, it exceeded the performance of a commercial q-PCR assay by achieving 100% accuracy, 100% sensitivity and 100% specificity. Click here to view the poster.

We are thrilled that these Australian based studies have shown agreement with international studies and look forward to continued collaborations that drive innovation in diagnostics.

For more information on The NG Biotech NG-test® Carba 5 or to discuss how this assay can support your laboratory, contact our team at Cell Biosciences. 

Click the images below to view the posters.